![KabukiLogo[6].png](https://static.wixstatic.com/media/1ead9f_e8540d7f011447e4b01583dd2417eccb~mv2.png/v1/fill/w_265,h_133,al_c,usm_0.66_1.00_0.01/KabukiLogo%5B6%5D.png)
RESEARCH PARTICIPATION OPPORTUNITIES
Dr. Jacqueline Harris, MD, Kennedy Krieger Institute/Johns Hopkins Medical Institution, specializes in patients with epigenetic disorders with neurologic and/or cognitive manifestations in Kabuki Syndrome. Dr. Harris is currently conducting several research studies and is seeking participants. Please see the individual study details below.
Virtual Research Study: Understanding Sleep, Behavior, and Quality of Life in Kabuki Syndrome
A Clinical Study of the Brain and Cognition in Kabuki Syndrome
A Pilot Trial of a Dietary Therapy for Kabuki Syndrome
LATEST NEWS & INFORMATION
Oryzon announces $1 million grant from Kabuki syndrome philanthropists to support a precision medicine Phase I/II trial with vafidemstat
-
HOPE will be the first clinical trial in precision medicine with vafidemstat in neurodevelopmental diseases
-
Multicentric study to assess the efficacy of vafidemstat in Kabuki Syndrome patients
-
Expected to start in early 2022
-
In collaboration with the Kennedy-Krieger Institute
